Ingrid van der Mei

List of Publications by Year
in descending order

170 papers	8,654 citations
57719 44 h-index	49868 87 g-index
171 all docs	171 docs citations
171 times ranked	7713 citing authors

#	Article	IF	Citations
1	Physical activity participation in Australians with multiple sclerosis: associations with geographical remoteness. Disability and Rehabilitation, 2023, 45, 1969-1974.	0.9	3
2	Physical activity, sitting time and exercise types, and associations with symptoms in Australian people with multiple sclerosis. Disability and Rehabilitation, 2022, 44, 1380-1388.	0.9	16
3	The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 831-841.	1.4	6
4	A proinflammatory diet is associated with an increased likelihood of first clinical diagnosis of central nervous system demyelination in women. Multiple Sclerosis and Related Disorders, 2022, 57, 103428.	0.9	5
5	Psychological impacts of COVID-19 pandemic on individuals living with multiple sclerosis: A rapid systematic review. Multiple Sclerosis and Related Disorders, 2022, 59, 103562.	0.9	5
6	Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression. Multiple Sclerosis and Related Disorders, 2022, 59, 103561.	0.9	10
7	Vitamin D metabolites and risk of first clinical diagnosis of central nervous system demyelination. Journal of Steroid Biochemistry and Molecular Biology, 2022, 218, 106060.	1.2	2
8	Evaluating the impact of the Understanding Multiple Sclerosis online course on participant MS knowledge, health literacy, resilience, self-efficacy, quality of life, and MS symptom severity. Multiple Sclerosis and Related Disorders, 2022, 60, 103717.	0.9	4
9	Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 723-731.	0.9	10
10	Long-term trajectories of employment status, workhours and disability support pension status, after a first episode of CNS demyelination. Multiple Sclerosis Journal, 2022, 28, 1793-1807.	1.4	2
11	Risk factors for leaving employment due to multiple sclerosis and changes in risk over the past decades: Using competing risk survival analysis. Multiple Sclerosis Journal, 2021, 27, 1250-1261.	1.4	6
12	Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with multiple sclerosis, irrespective of clinical phenotype. Multiple Sclerosis Journal, 2021, 27, 1262-1275.	1.4	20
13	Development and psychometric properties of the Multiple Sclerosis Knowledge Assessment Scale: Rasch analysis of a novel tool for evaluating MS knowledge. Multiple Sclerosis Journal, 2021, 27, 767-777.	1.4	5
14	High Prudent diet factor score predicts lower relapse hazard in early multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1112-1124.	1.4	10
15	Comorbidities contribute substantially to the severity of common multiple sclerosis symptoms. Journal of Neurology, 2021, 268, 559-568.	1.8	7
16	Estimating the relative contribution of comorbidities in predicting health-related quality of life of people with multiple sclerosis. Journal of Neurology, 2021, 268, 569-581.	1.8	11
17	Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis. Journal of Neurology, 2021, 268, 602-612.	1.8	11
18	Dietary patterns and associations with health outcomes in Australian people with multiple sclerosis. European Journal of Clinical Nutrition, 2021, 75, 1506-1514.	1.3	30

#	Article	IF	Citations
19	Assessing the consistency and validity of self-reported year of diagnosis among participants in a longitudinal study of people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 49, 102755.	0.9	1
20	Comorbidity patterns in people with multiple sclerosis: A latent class analysis of the Australian Multiple Sclerosis Longitudinal Study. European Journal of Neurology, 2021, 28, 2269-2279.	1.7	6
21	Identification of a Latitude Gradient in the Prevalence of Primary Biliary Cholangitis. Clinical and Translational Gastroenterology, 2021, 12, e00357.	1.3	4
22	197Assessment of Depression, Anxiety and Fatigue in relation to diet quality in Multiple Sclerosis. International Journal of Epidemiology, 2021, 50, .	0.9	0
23	100Identification of a latitude gradient in the prevalence of Primary Biliary Cholangitis in Australia. International Journal of Epidemiology, 2021, 50, .	0.9	0
24	937Rasch analysis of the Health Literacy Questionnaire in the Understanding Multiple Sclerosis online course cohort. International Journal of Epidemiology, 2021, 50, .	0.9	0
25	1256Psychological impacts of COVID-19 pandemic on individuals living with multiple sclerosis: a rapid systematic review. International Journal of Epidemiology, 2021, 50, .	0.9	0
26	Role of environmental factors in multiple sclerosis. Expert Review of Neurotherapeutics, 2021, 21, 1389-1408.	1.4	22
27	1234Smoking, infectious mononucleosis, early-life exposures and risk of progressive-onset Multiple Sclerosis: a case-control study. International Journal of Epidemiology, 2021, 50, .	0.9	0
28	Work productivity trajectories of Australians living with multiple sclerosis: A group-based modelling approach. Multiple Sclerosis and Related Disorders, 2021, 54, 103131.	0.9	9
29	101Pre-onset sun exposure significantly associated with risk of primary biliary cirrhosis. International Journal of Epidemiology, 2021, 50, .	0.9	0
30	Association between MS-related knowledge, health literacy, self-efficacy, resilience, and quality of life in a large cohort of MS community members: A cross-sectional study. Multiple Sclerosis and Related Disorders, 2021, 54, 103158.	0.9	3
31	Does health-related quality of life differ between people with relapse onset and progressive onset Multiple Sclerosis?. Multiple Sclerosis and Related Disorders, 2021, 54, 103138.	0.9	1
32	99Increasing prevalence of primary biliary cholangitis in Victoria, Australia. International Journal of Epidemiology, 2021, 50, .	0.9	0
33	Omega-3 Index, fish consumption, use of fish oil supplements and first clinical diagnosis of central nervous system demyelination. Multiple Sclerosis and Related Disorders, 2021, 55, 103210.	0.9	4
34	Impact of remoteness on patient outcomes for people with multiple sclerosis in Australia. Multiple Sclerosis and Related Disorders, 2021, 55, 103208.	0.9	2
35	Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology, 2021, 97, e1870-e1885.	1.5	168
36	Developing a clinical–environmental–genotypic prognostic index for relapsing-onset multiple sclerosis and clinically isolated syndrome. Brain Communications, 2021, 3, fcab288.	1.5	7

#	Article	IF	Citations
37	The Multiple Sclerosis Data Alliance Catalogue. International Journal of MS Care, 2021, 23, 261-268.	0.4	3
38	Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia. Multiple Sclerosis Journal, 2020, 26, 411-420.	1.4	18
39	Higher fish consumption and lower risk of central nervous system demyelination. European Journal of Clinical Nutrition, 2020, 74, 818-824.	1.3	15
40	Change in multiple sclerosis prevalence over time in Australia 2010â€"2017 utilising disease-modifying therapy prescription data. Multiple Sclerosis Journal, 2020, 26, 1315-1328.	1.4	30
41	Comorbidities are prevalent and detrimental for employment outcomes in people of working age with multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1550-1559.	1.4	16
42	Increasing prevalence of primary biliary cholangitis in Victoria, Australia. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 673-679.	1.4	10
43	The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders, 2020, 37, 101486.	0.9	11
44	Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. Multiple Sclerosis Journal, 2020, 26, 1765-1774.	1.4	10
45	Validation of 0â€"10 MS symptom scores in the Australian multiple sclerosis longitudinal study. Multiple Sclerosis and Related Disorders, 2020, 39, 101895.	0.9	14
46	COVID-19 in people with multiple sclerosis: A global data sharing initiative. Multiple Sclerosis Journal, 2020, 26, 1157-1162.	1.4	50
47	Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple Sclerosis Journal, 2020, 26, 1816-1821.	1.4	965
48	The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: Results from updated and detailed data on types of costs. Multiple Sclerosis and Related Disorders, 2020, 44, 102247.	0.9	15
49	Measuring the health-related quality of life in Australians with multiple sclerosis using the assessment of quality of life-8-dimension (AQoL-8D) multi-attribute utility instrument. Multiple Sclerosis and Related Disorders, 2020, 44, 102358.	0.9	12
50	Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 994-1004.	1.4	41
51	Patientâ€reported outcomes are worse for progressiveâ€onset multiple sclerosis than relapseâ€onset multiple sclerosis, particularly early in the disease process. European Journal of Neurology, 2019, 26, 155-161.	1.7	20
52	The role of nutritional factors during adolescence in multiple sclerosis onset: a population-based incident caseâ€"control study. Nutritional Neuroscience, 2019, 24, 1-8.	1.5	11
53	Modifiable factors associated with depression and anxiety in multiple sclerosis. Acta Neurologica Scandinavica, 2019, 140, 204-211.	1.0	16
54	A Higher Mediterranean Diet Score, Including Unprocessed Red Meat, Is Associated with Reduced Risk of Central Nervous System Demyelination in a Case-Control Study of Australian Adults. Journal of Nutrition, 2019, 149, 1385-1392.	1.3	36

#	Article	IF	Citations
55	Higher Non-processed Red Meat Consumption Is Associated With a Reduced Risk of Central Nervous System Demyelination. Frontiers in Neurology, 2019, 10, 125.	1.1	14
56	Oral health and behaviours of people living with Multiple Sclerosis in Australia. Community Dentistry and Oral Epidemiology, 2019, 47, 201-209.	0.9	4
57	Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1800-1808.	1.4	7
58	Vitamin D deficiency is an etiological factor for MS â€" Commentary. Multiple Sclerosis Journal, 2019, 25, 641-643.	1.4	2
59	Polymorphism in the serotonin transporter gene polymorphisms (5-HTTLPR) modifies the association between significant life events and depression in people with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 848-855.	1.4	6
60	Lifestyle factors and multiple sclerosis: A population-based incident case-control study. Multiple Sclerosis and Related Disorders, 2018, 22, 128-133.	0.9	22
61	The multiple sclerosis risk allele within the AHI1 gene is associated with relapses in children and adults. Multiple Sclerosis and Related Disorders, 2018, 19, 161-165.	0.9	15
62	Common genetic variation within miR-146a predicts disease onset and relapse in multiple sclerosis. Neurological Sciences, 2018, 39, 297-304.	0.9	19
63	Sun Exposure across the Life Course Significantly Modulates Early Multiple Sclerosis Clinical Course. Frontiers in Neurology, 2018, 9, 16.	1.1	30
64	Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset. Frontiers in Neurology, 2018, 9, 418.	1.1	8
65	Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1200-1207.	0.9	41
66	The Role of Vitamin D in Multiple Sclerosis: Biology and Biochemistry, Epidemiology and Potential Roles in Treatment. Medicinal Chemistry, 2018, 14, 129-143.	0.7	18
67	Response to Attarian regarding article. Acta Neurologica Scandinavica, 2017, 135, 382-382.	1.0	0
68	Predictors of Beagleyâ€"Gibson skin cast grade in older adults. Skin Research and Technology, 2017, 23, 235-242.	0.8	7
69	Variation within MBP gene predicts disease course in multiple sclerosis. Brain and Behavior, 2017, 7, e00670.	1.0	17
70	Environmental and genetic determinants of two vitamin D metabolites in healthy Australian children. Journal of Pediatric Endocrinology and Metabolism, 2017, 30, 531-541.	0.4	2
71	Validation of Sun Exposure Reported Annually Against Interim Selfâ€report and Daily Sun Diaries. Photochemistry and Photobiology, 2017, 93, 1294-1302.	1.3	3
72	An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 395-401.	0.9	71

#	Article	IF	Citations
73	Association between human herpesvirus & human endogenous retrovirus and MS onset & progression. Journal of the Neurological Sciences, 2017, 372, 239-249.	0.3	24
74	Midsagittal corpus callosum area and conversion to multiple sclerosis after clinically isolated syndrome: A multicentre Australian cohort study. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 453-460.	0.9	6
75	Closing the gap: Longitudinal changes in employment for Australians with multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1415-1423.	1.4	17
76	Genetic variation in the gene *LRP2* increases relapse risk in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 864-868.	0.9	21
77	Waterpipe smoking associated with multiple sclerosis: A population-based incident case–control study. Multiple Sclerosis Journal, 2017, 23, 1328-1335.	1.4	39
78	Stressful life events and the risk of initial central nervous system demyelination. Multiple Sclerosis Journal, 2017, 23, 1000-1007.	1.4	14
79	The impact of multiple sclerosis severity on health state utility values: Evidence from Australia. Multiple Sclerosis Journal, 2017, 23, 1157-1166.	1.4	28
80	Anxiety, depression and fatigue at 5‐year review following CNS demyelination. Acta Neurologica Scandinavica, 2016, 134, 403-413.	1.0	47
81	Synergetic and antagonistic effects of combined calcitriol and interferon-β treatment on cytokine production by stimulated PBMCs. Journal of Neuroimmunology, 2016, 297, 148-155.	1.1	1
82	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1343-1349.	0.9	63
83	Association between exposure to farm animals and pets and risk of Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2016, 10, 53-56.	0.9	8
84	Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies. Neurology: Genetics, 2016, 2, e87.	0.9	76
85	Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1204-1211.	0.9	38
86	Investigating the patterns and determinants of seasonal variation in vitamin D status in Australian adults: the Seasonal D Cohort Study. BMC Public Health, 2016, 16, 892.	1.2	15
87	Self‐Reported Changes in Sun‐Protection Behaviors at Different Latitudes in Australia. Photochemistry and Photobiology, 2016, 92, 495-502.	1.3	3
88	Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1655-1664.	1.4	44
89	Frequency of Comorbidities and Their Association with Clinical Disability and Relapse in Multiple Sclerosis. Neuroepidemiology, 2016, 46, 106-113.	1.1	45
90	Higher intake of omega-3 polyunsaturated fatty acids is associated with a decreased risk of a first clinical diagnosis of central nervous system demyelination: Results from the Ausimmune Study. Multiple Sclerosis Journal, 2016, 22, 884-892.	1.4	80

#	Article	IF	Citations
91	Population attributable fractions and joint effects of key risk factors for multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 461-469.	1.4	59
92	Weekly cholecalciferol supplementation results in significant reductions in infection risk among the vitamin D deficient: results from the CIPRIS pilot RCT. BMC Nutrition, 2015, 1, .	0.6	11
93	The role of epidemiology in MS research: Past successes, current challenges and future potential. Multiple Sclerosis Journal, 2015, 21, 969-977.	1.4	37
94	Cumulative risks and cessation of exclusive breast feeding: Australian cross-sectional survey. Archives of Disease in Childhood, 2015, 100, 863-868.	1.0	22
95	Genetic variation in PBMC-produced IFN-Î³ and TNF-Î± associations with relapse in multiple sclerosis. Journal of the Neurological Sciences, 2015, 349, 40-44.	0.3	5
96	Weekend personal ultraviolet radiation exposure in four cities in Australia: Influence of temperature, humidity and ambient ultraviolet radiation. Journal of Photochemistry and Photobiology B: Biology, 2015, 143, 74-81.	1.7	21
97	Modulating effects of <i>WT1</i> on interferon-<i>Î²</i>-vitamin D association in MS. Acta Neurologica Scandinavica, 2015, 131, 231-239.	1.0	14
98	The co-occurrence of multiple sclerosis and type 1 diabetes: Shared aetiologic features and clinical implication for MS aetiology. Journal of the Neurological Sciences, 2015, 348, 126-131.	0.3	39
99	Stimulated PBMC-produced IFN-Â and TNF-Â are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 200-207.	0.9	27
100	The relationship between ambient ultraviolet radiation (UVR) and objectively measured personal UVR exposure dose is modified by season and latitude. Photochemical and Photobiological Sciences, 2014, 13, 1711-1718.	1.6	28
101	Vascular comorbidities in the onset and progression of multiple sclerosis. Journal of the Neurological Sciences, 2014, 347, 23-33.	0.3	71
102	Measuring Exposure to Solar Ultraviolet Radiation Using a Dosimetric Technique: Understanding Participant Compliance Issues. Photochemistry and Photobiology, 2014, 90, 919-924.	1.3	6
103	An adverse lipid profile is associated with disability and progression in disability, in people with MS. Multiple Sclerosis Journal, 2014, 20, 1737-1744.	1.4	123
104	The Contributions of Solar Ultraviolet Radiation Exposure and Other Determinants to Serum 25-Hydroxyvitamin D Concentrations in Australian Adults: The AusD Study. American Journal of Epidemiology, 2014, 179, 864-874.	1.6	84
105	Meta-Analyses to Investigate Gene-Environment Interactions in Neuroepidemiology. Neuroepidemiology, 2014, 42, 39-49.	1.1	7
106	Higher levels of reported sun exposure, and not vitamin D status, are associated with less depressive symptoms and fatigue in multiple sclerosis. Acta Neurologica Scandinavica, 2014, 129, 123-131.	1.0	54
107	Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1209-1213.	0.9	35
108	The potential role of epigenetic modifications in the heritability of multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 135-140.	1.4	29

#	Article	IF	Citations
109	Novel modulating effects of PKC family genes on the relationship between serum vitamin D and relapse in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 399-404.	0.9	32
110	EBV & HHV6 reactivation is infrequent and not associated with MS clinical course. Acta Neurologica Scandinavica, 2014, 130, 328-337.	1.0	26
111	Association between multiple sclerosis risk-associated SNPs and relapse and disability â€" a prospective cohort study. Multiple Sclerosis Journal, 2014, 20, 313-321.	1.4	23
112	Adverse lipid profile is not associated with relapse risk in MS: Results from an observational cohort study. Journal of the Neurological Sciences, 2014, 340, 230-232.	0.3	33
113	Lipids in multiple sclerosis: adverse lipid profiles, disability and disease progression. Clinical Lipidology, 2014, 9, 473-475.	0.4	1
114	Vitamin D status: Multifactorial contribution of environment, genes and other factors in healthy Australian adults across a latitude gradient. Journal of Steroid Biochemistry and Molecular Biology, 2013, 136, 300-308.	1.2	78
115	Vitamin D and multiple sclerosis. Journal of Clinical Neuroscience, 2013, 20, 634-641.	0.8	41
116	Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 217-224.	1.4	234
117	Assessing interactions between HLA-DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1355-1358.	1.4	17
118	Occupational Exposure and Risk of Central Nervous System Demyelination. American Journal of Epidemiology, 2013, 177, 954-961.	1.6	17
119	The AusD Study: A Population-based Study of the Determinants of Serum 25-Hydroxyvitamin D Concentration Across a Broad Latitude Range. American Journal of Epidemiology, 2013, 177, 894-903.	1.6	23
120	Early-life hygiene-related factors affect risk of central nervous system demyelination and asthma differentially. Clinical and Experimental Immunology, 2013, 172, 466-474.	1.1	17
121	The physical anthropometry, lifestyle habits and blood pressure of people presenting with a first clinical demyelinating event compared to controls: The Ausimmune study. Multiple Sclerosis Journal, 2013, 19, 1717-1725.	1.4	30
122	Sun Exposure over a Lifetime in Australian Adults from Latitudinally Diverse Regions. Photochemistry and Photobiology, 2013, 89, 737-744.	1.3	22
123	Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 799-806.	1.4	51
124	The genetics of multiple sclerosis. Practical Neurology, 2012, 12, 279-288.	0.5	36
125	Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology, 2012, 79, 254-260.	1.5	90
126	Adherence to <scp>MRI</scp> protocol consensus guidelines in multiple sclerosis: An <scp>A</scp>ustralian multiâ€centre study. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 594-598.	0.9	14

#	Article	IF	Citations
127	Vitamin <scp>D</scp> deficiency in <scp>T</scp>asmania: a whole of life perspective. Internal Medicine Journal, 2012, 42, 1137-1144.	0.5	9
128	Offspring number, pregnancy, and risk of a first clinical demyelinating event. Neurology, 2012, 78, 867-874.	1.5	122
129	Vitamin D and the musculoskeletal health of older adults. Australian Family Physician, 2012, 41, 92-9.	0.5	13
130	Individual and Joint Action of Environmental Factors and Risk of MS. Neurologic Clinics, 2011, 29, 233-255.	0.8	63
131	The role of latitude, ultraviolet radiation exposure and vitamin D in childhood asthma and hayfever: an Australian multicenter study. Pediatric Allergy and Immunology, 2011, 22, 327-333.	1.1	78
132	Role of vitamin D in multiple sclerosis: implications for disease management. Neurodegenerative Disease Management, 2011, 1, 523-536.	1.2	4
133	Trends in the epidemiology of multiple sclerosis in Greater Hobart, Tasmania: 1951 to 2009. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 180-187.	0.9	43
134	Heterogeneity at the HLA-DRB1 allelic variation locus does not influence multiple sclerosis disease severity, brain atrophy or cognition. Multiple Sclerosis Journal, 2011, 17, 344-352.	1.4	40
135	Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1132-1141.	0.9	556
136	Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. Neurology, 2011, 77, 371-379.	1.5	71
137	Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology, 2011, 76, 540-548.	1.5	324
138	Human leukocyte antigen–DR15, low infant sibling exposure and multiple sclerosis: Gene–environment interaction. Annals of Neurology, 2010, 67, 261-265.	2.8	24
139	Higher 25–hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Annals of Neurology, 2010, 68, 193-203.	2.8	388
140	Multiple Sclerosis Susceptibility-Associated SNPs Do Not Influence Disease Severity Measures in a Cohort of Australian MS Patients. PLoS ONE, 2010, 5, e10003.	1.1	45
141	Latitudinal variation in incidence and type of first central nervous system demyelinating events. Multiple Sclerosis Journal, 2010, 16, 398-405.	1.4	80
142	Combined effects of smoking, anti-EBNA antibodies, and <i>HLA-DRB1*1501</i> on multiple sclerosis risk. Neurology, 2010, 74, 1365-1371.	1.5	124
143	Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. Neurology, 2009, 73, 1018-1025.	1.5	39
144	Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 Vitamin D receptor variant in this interaction. Multiple Sclerosis Journal, 2009, 15, 563-570.	1.4	82

#	ARTICLE	IF	CITATIONS
145	Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. Journal of Neurology, 2009, 256, 577-585.	1.8	117
146	Associations between Silicone Skin Cast Score, Cumulative Sun Exposure, and Other Factors in the Ausimmune Study: A Multicenter Australian Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2887-2894.	1.1	52
147	Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiology and Drug Safety, 2008, 17, 565-576.	0.9	73
148	CTLA-4 and multiple sclerosis: The A49G single nucleotide polymorphism shows no association with multiple sclerosis in a Southern Australian population. Journal of Neuroimmunology, 2008, 196, 139-142.	1.1	8
149	Validation of linear cerebral atrophy markers in multiple sclerosis. Journal of Clinical Neuroscience, 2008, 15, 130-137.	0.8	47
150	Monthly Ambient Sunlight, Infections and Relapse Rates in Multiple Sclerosis. Neuroepidemiology, 2008, 31, 271-279.	1.1	142
151	Melanocortin 1 receptor genotype, past environmental sun exposure, and risk of multiple sclerosis. Neurology, 2008, 71, 583-589.	1.5	46
152	Observational analytic studies in multiple sclerosis: controlling bias through study design and conduct. The Australian Multicentre Study of Environment and Immune Function. Multiple Sclerosis Journal, 2007, 13, 827-839.	1.4	68
153	The High Prevalence of Vitamin D Insufficiency across Australian Populations Is Only Partly Explained by Season and Latitude. Environmental Health Perspectives, 2007, 115, 1132-1139.	2.8	198
154	The effect of season on cytokine expression in multiple sclerosis and healthy subjects. Journal of Neuroimmunology, 2007, 188, 181-186.	1.1	22
155	Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. Journal of Neurology, 2007, 254, 581-590.	1.8	285
156	Asthma onset prior to multiple sclerosis and the contribution of sibling exposure in early life. Clinical and Experimental Immunology, 2006, 146, 463-470.	1.1	34
157	Validity and Reliability of Adult Recall of Past Sun Exposure in a Case-Control Study of Multiple Sclerosis. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1538-1544.	1.1	100
158	UVR, Vitamin D and Three Autoimmune Diseases—Multiple Sclerosis, Type 1 Diabetes, Rheumatoid Arthritis. Photochemistry and Photobiology, 2005, 81, 1267.	1.3	186
159	Birth order, infection in early life, and multiple sclerosis. Lancet Neurology, The, 2005, 4, 793-794.	4.9	6
160	Exposure to Infant Siblings During Early Life and Risk of Multiple Sclerosis—Reply. JAMA - Journal of the American Medical Association, 2005, 293, 2089.	3.8	2
161	Exposure to Infant Siblings During Early Life and Risk of Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2005, 293, 463.	3.8	137
162	What affects your MS? Responses to an anonymous, Internet-based epidemiological survey. Multiple Sclerosis Journal, 2004, 10, 202-211.	1.4	68

#	Article	IF	Citations
163	Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ: British Medical Journal, 2003, 327, 316-0.	2.4	457
164	PAST SUN EXPOSURE, SKIN PHENOTYPE AND RISK OF MULTIPLE SCLEROSIS. Epidemiology, 2003, 14, S113-S114.	1.2	4
165	Genetic Dissection of the Human Leukocyte Antigen Region by Use of Haplotypes of Tasmanians with Multiple Sclerosis. American Journal of Human Genetics, 2002, 70, 1125-1137.	2.6	93
166	Misclassification due to body hair and seasonal variation on melanin density estimates for skin type using spectrophotometry. Journal of Photochemistry and Photobiology B: Biology, 2002, 68, 45-52.	1.7	22
167	Ultraviolet radiation and autoimmune disease: insights from epidemiological research. Toxicology, 2002, 181-182, 71-78.	2.0	175
168	Regional Variation in Multiple Sclerosis Prevalence in Australia and Its Association with Ambient Ultraviolet Radiation. Neuroepidemiology, 2001, 20, 168-174.	1.1	195
169	Contact dermatitis in Alstroemeria workers. Occupational Medicine, 1998, 48, 397-404.	0.8	17
170	Estimating the impact of work difficulties, work self-efficacy and work psychological safety on MS-related work productivity loss. Multiple Sclerosis Journal, 0, , 135245852210975.	1.4	0